This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

47/100

✓ Peer-reviewed alzhub usefulness score 47 out of 100. End-of-life care

Topic: Risk, prevention and care in population studies

In long-term care residents, ADL scores worsened by a mean of 0.29 points (95%CI = 0.27, 0.31) per 3 months and antihypertensive deprescribing did not impact this worsening (difference between groups -0.04 points every 3 months, 95%CI = -0.15, 0.06). In the non-dementia subgroup, ADL worsened by 0.15 points (95%CI = 0.11, 0.19) every 3 months. However, residents who were deprescribed showed a slightly improved ADL score over time while the continued users showed ADL decline (difference between groups -0.23 points every 3 months, 95%CI = -0.43, -0.03). Deprescribing was not associated with ADL change in the dementia subgroup. The intention-to-treat results were not meaningfully different. Antihypertensive deprescribing did not have a deleterious effect on functional status in long-term care residents with or without dementia. This may be reassuring to residents and clinicians who are considering antihypertensive medication reduction or discontinuation in long-term care settings.

Key findings

In long-term care residents, ADL scores worsened by a mean of 0.29 points (95%CI = 0.27, 0.31) per 3 months and antihypertensive deprescribing did not impact this worsening (difference between groups -0.04 points every 3 months, 95%CI = -0.15, 0.06).
In the non-dementia subgroup, ADL worsened by 0.15 points (95%CI = 0.11, 0.19) every 3 months.
However, residents who were deprescribed showed a slightly improved ADL score over time while the continued users showed ADL decline (difference between groups -0.23 points every 3 months, 95%CI = -0.43, -0.03).
Deprescribing was not associated with ADL change in the dementia subgroup.
The intention-to-treat results were not meaningfully different.

Why it matters

In long-term care residents, antihypertensive deprescribing did not worsen functional status in those with or without dementia, and in the non-dementia subgroup deprescribed residents showed slightly improved scores. This concerns medication reduction and function, not treating, curing or preventing Alzheimer's disease.

Study details

Participants12,238
Evidence strengthLow

How this study scored 47/100

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Journal of the American Geriatrics Society)
Journal's citation record	3 / 4	Journal of the American Geriatrics Society: journal h-index 344 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	4 / 4	12,238 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	1 / 7	Cited 2 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.7 citations a year over 3 year(s) since 2025
Impact for its field and year	2 / 6	Cited 1.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	3 / 4	Last-listed author Michelle C. Odden: h-index 51 (OpenAlex, whole career)
Institution's track record	3 / 3	Stanford University: institution h-index 2,684 (OpenAlex)
Multi-centre collaboration	2 / 3	OpenAlex lists 8 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 39750005)
Free to read	2 / 2	Free to read
Total	47 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Liu, X., Graham, L. A., Jing, B., Dave, C. V., Li, Y., Tamura, M. K., et al. (2025). Antihypertensive Deprescribing and Functional Status in VA Long‐Term Care Residents With and Without Dementia. Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.19342

Vancouver

Liu X, Graham LA, Jing B, Dave CV, Li Y, Tamura MK, et al. Antihypertensive Deprescribing and Functional Status in VA Long‐Term Care Residents With and Without Dementia. Journal of the American Geriatrics Society. 2025. doi:10.1111/jgs.19342. PMID: 39750005.

BibTeX

@article{liu2025-39750005,
  author  = {Liu, Xiaojuan and Graham, Laura A. and Jing, Bocheng and Dave, Chintan V. and Li, Yongmei and Tamura, Manjula Kurella and Steinman, Michael Alan and Lee, Sei J. and others},
  title   = {{Antihypertensive Deprescribing and Functional Status in VA Long‐Term Care Residents With and Without Dementia}},
  journal = {Journal of the American Geriatrics Society},
  year    = {2025},
  doi     = {10.1111/jgs.19342},
  pmid    = {39750005},
  url     = {https://doi.org/10.1111/jgs.19342}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in End-of-life care

Similar studies

More on End-of-life care

See all studies in End-of-life care →